Request To Download Free Sample of This Strategic Report @- The Global Xerostomia Therapeutics Market is poised for significant growth, with an anticipated reach of over USD 822.14 million by 2026, ...
A frequent reason for discontinuation of therapy is dry mouth, which is reported by as many as 80% of patients receiving the immediate-release formulation of oxybutynin (widely considered the ...